EA201201514A1 - Лечение аутоиммунных заболеваний - Google Patents

Лечение аутоиммунных заболеваний

Info

Publication number
EA201201514A1
EA201201514A1 EA201201514A EA201201514A EA201201514A1 EA 201201514 A1 EA201201514 A1 EA 201201514A1 EA 201201514 A EA201201514 A EA 201201514A EA 201201514 A EA201201514 A EA 201201514A EA 201201514 A1 EA201201514 A1 EA 201201514A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
alkoxy
halogen
phenyl
trihalogenomethyl
Prior art date
Application number
EA201201514A
Other languages
English (en)
Russian (ru)
Inventor
Петер Гергели
Эрик Валлстрём
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201514(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201201514A1 publication Critical patent/EA201201514A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201201514A 2010-05-06 2011-05-05 Лечение аутоиммунных заболеваний EA201201514A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06
PCT/EP2011/057203 WO2011138393A1 (en) 2010-05-06 2011-05-05 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
EA201201514A1 true EA201201514A1 (ru) 2013-05-30

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201514A EA201201514A1 (ru) 2010-05-06 2011-05-05 Лечение аутоиммунных заболеваний

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) * 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4152884B2 (ja) * 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
KR100913269B1 (ko) * 2001-09-27 2009-08-21 교린 세이야꾸 가부시키 가이샤 디아릴 황화물 유도체, 그의 염 및 이를 이용한 면역억제제
JP4571497B2 (ja) * 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
DK1602660T3 (da) * 2003-02-18 2011-05-23 Kyorin Seiyaku Kk Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
US7612064B2 (en) * 2003-05-26 2009-11-03 Takeda Pharmaceutical Company Limited Sulfopyrroles
EP1660449B1 (en) 2003-08-28 2009-11-18 Novartis AG Aminopropanol derivatives
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
NZ566137A (en) * 2005-09-09 2011-05-27 Novartis Ag The use of diphenyl thioether derivatives to treat autoimmune diseases

Also Published As

Publication number Publication date
BR112012028190A2 (pt) 2016-08-02
KR20130066630A (ko) 2013-06-20
PE20130612A1 (es) 2013-06-06
CU20120154A7 (es) 2013-03-27
TW201201814A (en) 2012-01-16
EP2566470A1 (en) 2013-03-13
IL222690A0 (en) 2012-12-31
CA2795394A1 (en) 2011-11-10
US20130172297A1 (en) 2013-07-04
MA34285B1 (fr) 2013-06-01
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
JP2013530937A (ja) 2013-08-01
NZ603999A (en) 2014-06-27
ZA201207710B (en) 2013-06-26
WO2011138393A1 (en) 2011-11-10
TN2012000509A1 (en) 2014-04-01
AU2011249784A1 (en) 2012-12-20
CR20120566A (es) 2013-01-09
AU2011249784B2 (en) 2014-03-06
CN102869353A (zh) 2013-01-09
CL2012003091A1 (es) 2013-03-22
MX2012012926A (es) 2012-12-17
ECSP12012312A (es) 2012-12-28

Similar Documents

Publication Publication Date Title
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
MX375261B (es) Compuestos aromaticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepatica, la fibrosis de la piel y la fibrosis cardiaca.
MX2021001486A (es) Inhibidores prmt5.
JP2012506389A5 (enExample)
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA200970856A1 (ru) Ингибиторы пути хеджхога
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
EA201691939A1 (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201170456A1 (ru) Синергические комбинации макроциклического ингибитора вируса гепатита с и нуклеозида
EA201000120A1 (ru) Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
EA201000104A1 (ru) Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
EA201101298A1 (ru) Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh
EA022994B1 (ru) Способ подавления толерантности к опиоидному анальгетику
UY31824A (es) Nuevos compuestos
JP2013538218A5 (enExample)
AR098319A1 (es) Profármacos de antagonista de nmda
EA201270653A1 (ru) Антагонист dpи его применение